Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Aravive Receives $6M Development Milestone From 3D Medicines

Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone
byBill Haddad
October 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the initiation of the global Phase 3 platinum resistant ovarian cancer (PROC) clinical trial in China for the development of Aravive’s batiraxcept.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Psychedelics Investor Acquires Firm With First-Mover Advantage In Safe Supply Narcotics Sector

By Joana Scopel
January 31, 7:47 PM
Late Tuesday, Origin Therapeutics Holdings Inc. (CSE: ORIG), an investment issuer that has historically focused on psychedelics-industry-related companies announced it had signed a binding Letter of Intent (LOI) to acquire all of the issued and outstanding securities of Safe Supply Streaming Co., a pharmaceutical streaming and investment company in the safe supply eco

CSE:ORIG